(Q44503694)

3 December 2017

title

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran (English)

1 reference

3 December 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Ulf G Eriksson

1

1 reference

3 December 2017

Susanne Johansson

2

1 reference

3 December 2017

Per-Ola Attman

3

1 reference

3 December 2017

Henrik Mulec

4

1 reference

3 December 2017

Lars Frison

5

1 reference

3 December 2017

Gunnar Fager

6

1 reference

3 December 2017

Ola Samuelsson

7

1 reference

3 December 2017

publication date

1 January 2003

1 reference

Clinical Pharmacokinetics

3 December 2017

published in

1 reference

3 December 2017

volume

42

1 reference

3 December 2017

issue

8

1 reference

3 December 2017

page(s)

743-753

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200342080-00003

3 December 2017

exact match

0 references

cites work

A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibiti

1 reference

12 December 2020

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT

1 reference

12 December 2020

New anticoagulant drugs

1 reference

12 December 2020

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

1 reference

12 December 2020

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

12 December 2020

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

1 reference

12 December 2020

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

1 reference

12 December 2020

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis

1 reference

12 December 2020

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

1 reference

12 December 2020

Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

12 December 2020

Measurement of renal function during drug development

1 reference

12 December 2020

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

1 reference

12 December 2020

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

1 reference

12 December 2020

10.2165/00003088-200342080-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

3 December 2017

1005903970

0 references

Fatcat ID

release_ja7a6vf7mfffzmc2xt6im5myh4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ja7a6vf7mfffzmc2xt6im5myh4

24 November 2022

mapped directly with Wikidata item

1 reference